### Highlights of This Issue  1693

#### SPECIAL FEATURES

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1695</td>
<td>Metformin: A Therapeutic Opportunity in Breast Cancer</td>
<td>Ana M. Gonzalez-Angulo, and Funda Meric-Bernstam</td>
</tr>
<tr>
<td>1701</td>
<td>Death Receptor Agonists as a Targeted Therapy for Cancer</td>
<td>Jeffrey Wiezorek, Pamela Holland, and Jonathan Graves</td>
</tr>
</tbody>
</table>

#### CCR Special Focus

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1709</td>
<td>Phase I Clinical Trials: Overcoming Barriers</td>
<td>Susan E. Bates</td>
</tr>
<tr>
<td>1710</td>
<td>An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics</td>
<td>Patricia M. LoRusso, Scott A. Boerner, and Lesley Seymour</td>
</tr>
<tr>
<td>1719</td>
<td>Information Needed to Conduct First-in-Human Oncology Trials in the United States: A View from a Former FDA Medical Reviewer</td>
<td>Adrian M. Senderowicz</td>
</tr>
<tr>
<td>1726</td>
<td>Approaches to Phase I Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee</td>
<td>S. Percy Ivy, Lillian L. Siu, Elizabeth Garrett-Mayer, and Larry Rubinstein</td>
</tr>
<tr>
<td>1737</td>
<td>Performing Phase I Clinical Trials of Anticancer Agents: Perspectives from within the European Union and Japan</td>
<td>Martin D. Forster, Nagahiro Saijo, Lesley Seymour, and Hilary Calvert</td>
</tr>
</tbody>
</table>

### Molecular Pathways

#### Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents


#### GCP Data Quality for Early Clinical Development

Edwin P. Rock, Vernetta J. Molloy, and Jeffrey S. Humphrey

#### The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee

Lesley Seymour, S. Percy Ivy, Daniel Sargent, David Spriggs, Laurence Baker, Larry Rubinstein, Mark J. Ratain, Michael Le Blanc, David Stewart, John Crowley, Susan Groshen, Jeffrey S. Humphrey, Pamela West, and Donald Berry

#### New Developments in Tyrosine Kinase Inhibitor Therapy for Newly Diagnosed Chronic Myeloid Leukemia

Philipp le Coutre, Michaela Schwarz, and Theo D. Kim

#### Overexpression of Smoothened Activates the Sonic Hedgehog Signaling Pathway in Pancreatic Cancer–Associated Fibroblasts

Kimberly Walter, Noriyuki Omura, Seung-Mo Hong, Margaret Griffith, Audrey Vincent, Michael Borges, and Michael Goggins

---

The Journal of Clinical and Translational Research

www.aacrjournals.org
IMAGING, DIAGNOSIS, PROGNOSIS

1790
Intratumoral Estrogen Disposition in Breast Cancer
Ben P. Haynes, Anne Hege Straume, Jürgen Geisler, Roger A’Hern, Hildegunn Helle, Ian E. Smith, Per E. Lønning, and Mitch Dowsett

1802
PEA-15 Inhibits Tumorigenesis in an MDA-MB-468 Triple-Negative Breast Cancer Xenograft Model through Increased Cytoplasmic Localization of Activated Extracellular Signal-Regulated Kinase
Chandra Bartholomeusz, Ana M. Gonzalez-Angulo, Anna Kazansky, Savitri Krishnamurthy, Ping Liu, Linda X. H. Yuan, Fumiyuki Yamasaki, Shuying Liu, Naoki Hayashi, Dongwei Zhang, Francisco J. Esteva, Gabriel N. Hortobagyi, and Naoto T. Ueno

1812
Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer

1824
The Oncogene DEK Promotes Leukemic Cell Survival and Is Downregulated by both Nutlin-3 and Chlorambucil in B-Chronic Lymphocytic Leukemia
Paola Secchiero, Rebecca Voltan, Maria Grazia di Iasio, Elisabetta Melloni, Mario Tiribelli, and Giorgio Zauli

1834
Targeted Inhibition of Inducible Nitric Oxide Synthase Inhibits Growth of Human Melanoma In vivo and Synergizes with Chemotherapy
Andrew G. Sikora, Alexander Gelbard, Michael A. Davies, Daisuke Sano, Suhendan Ekmeckioglu, John Kwon, Yared Hailemichael, Padmini Jayaraman, Jeffrey N. Myers, Elizabeth A. Grimm, and Willem W. Overwijk

1845
The Role of the CpG Island Methylator Phenotype in Colorectal Cancer Prognosis Depends on Microsatellite Instability Screening Status
Anna M. Dahlin, Richard Palmqvist, Maria L. Henriksen, Maria Jacobsson, Vincy Eklof, Jürgen Rutegård, Ake Öberg, and Bethany R. Van Guelpen

1856
Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome

1865
Highly Phosphorylated FOXO3A Is an Adverse Prognostic Factor in Acute Myeloid Leukemia
Steven M. Kornblau, Neera Singh, YiHua Qiu, Wenjing Chen, Nianxian Zhang, and Kevin R. Coombes

1875
Value of Magnetic Resonance Spectroscopy Imaging and Dynamic Contrast-Enhanced Imaging for Detecting Prostate Cancer Foci in Men With Prior Negative Biopsy
Alessandro Sciarr, Valeria Panebianco, Mauro Circariello, Stefano Sracchia, Susanna Cattarino, Danilo Lis, Alessandro Gentilucci, Andrea Alfarone, Silvia Bernardo, Roberto Passariello, and Vincenzo Gentile

1884
Obesity Is an Independent Prognostic Variable in Colon Cancer Survivors
Frank A. Sinicrope, Nathan R. Foster, Daniel J. Sargent, Michael J. O’Connell, and Cathryn Rankin

CANCER THERAPY: PRECLINICAL

1802
Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial
Alan S. Wayne, Robert J. Kreitman, Harry W. Findley, Glen Lew, Cynthia Delbrook, Seth M. Steinberg, Maryalice Stetler-Stevenson, David J. FitzGerald, and Ira Pastan
Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer
Massimo Cristofanilli, Vicente Valero, Aroop Mangalik, Melanie Royce, Ian Rabinowitz, Francis P. Arena, Joan F. Kroener, Elizabeth Cucio, Claire Watkins, Sarah Bacus, Elsa M. Cota, Elizabeth Anderson, and Patrick J. Magill

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies
Bart Kuenen, Petronella O. Witteveen, Rita Ruijter, Giuseppe Giaccone, Aruna Dontabhaktuni, Floyd Fox, Terry Katz, Hagop Youssoufian, Junming Zhu, Eric K. Rowinsky, and Emile E. Voest

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
Patricia M. LoRusso, Smitha S. Krishnamurthi, John J. Rinehart, Lisle M. Nabell, Lisa Malburg, Paul B. Chapman, Samuel E. DePrimo, Steven Bentivegna, Keith D. Wilner, Weiwei Tan, and Alejandro D. Ricart

Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer

SUSCEPTIBILITY AND PREVENTION

Mesalazine Reduces Mutations in Transforming Growth Factor β Receptor II and Activin Type II Receptor by Improvement of Replication Fidelity in Mononucleotide Repeats
Christoph Campregher, Clemens Honeder, Heekyung Chung, John M. Carethers, and Christoph Gasche

A High Proportion of DNA Variants of BRCA1 and BRCA2 Is Associated with Aberrant Splicing in Breast/Ovarian Cancer Patients
David J. Sanz, Alberto Acedo, Mar Infante, Mercedes Durán, Lucía Pérez-Cabornero, Eva Esteban-Cardenosa, Enrique Lastra, Franco Pagani, Cristina Miner, and Eladio A. Velasco

LETTERS TO THE EDITOR

Correlation of Segmented Metabolic Tumor Volume with Outcome - Letter

Correlation of Segmented Metabolic Tumor Volume with Outcome - Response
Man Ki Chung, Chung-Hwan Baek, and Joon Young Choi,
ABOUT THE COVER

Human pancreatic cancer–associated fibroblasts (CAFs) overexpress the Hedgehog receptor SMO. Here, immunohistochemical labeling highlights overexpression of Smo protein in a human primary pancreatic adenocarcinoma. Strong Smo expression is detected in stromal fibroblasts adjacent to pancreatic cancer cells. For details, see the article by Walter and colleagues on page 1781 of this issue.